Chiesi and Protalix Secure EC Approval for Extended Dosing Regimen of Fabry Disease Therapy
Event summary
- European Commission approved a 2mg/kg every-4-weeks dosing regimen for pegunigalsidase alfa (Elfabrio®) in adults with stable Fabry disease.
- Approval follows positive opinion from the EMA's Committee for Medicinal Products for Human Use (CHMP).
- Protalix BioTherapeutics is entitled to a $25 million regulatory milestone payment from Chiesi.
- Approval based on data from the BRIGHT study and its ongoing extension study CLI-06657AA1-03.
The big picture
The approval represents a strategic win for Chiesi and Protalix in the competitive Fabry disease treatment landscape, where dosing convenience can differentiate therapies. This move aligns with broader industry trends toward patient-centric care delivery in rare diseases, potentially setting a precedent for other enzyme replacement therapies. The $25 million milestone payment underscores the financial significance of this regulatory achievement.
What we're watching
- Market Adoption
- How quickly EU countries will integrate the new dosing regimen into national treatment guidelines and reimbursement policies.
- Commercial Impact
- Whether the extended dosing interval will drive broader adoption of Elfabrio® among Fabry disease patients and physicians.
- Pipeline Progress
- The pace at which Protalix and Chiesi can advance other candidates in their rare disease pipeline following this regulatory success.